Exhibit 10.29 Confidential Execution Version [***] Certain information in this document has been  {E1 excluded}  pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely  {E2 cause}  competitive {E158 harm} to the registrant if publicly  {E3 disclosed}  .  NOV 02, 2019

BIOEQ IP AG

AND

COHERUS BIOSCIENCES, INC. LICENSE AND DEVELOPMENT AGREEMENT

Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version CONTENTS

Clause Page

1. DEFINITIONS AND INTERPRETATION1

2. LICENSE GRANT10

3. DEVELOPMENT11

4. REGULATORY ACTIVITIES14

5. MANUFACTURING AND SUPPLY17

6. COMMERCIALIZATION18

7. FINANCIAL PROVISIONS20

8. TAXATION23

9. INTELLECTUAL PROPERTY24

10. COVENANTS  {E4 RELATING}  TO THE [***] AGREEMENT30

11. CONFIDENTIALITY30

12. REPRESENTATIONS, WARRANTIES AND COVENANTS32

13. INDEMNIFICATION AND LIMITATION OF LIABILITY34

14. GOVERNANCE35

15. TERM AND TERMINATION; NON-SOLICITATION37

16. GENERAL PROVISIONS43

Schedules

Annex 1: [***] Agreement

Annex 2:  Term  Sheet for Manufacturing and Supply Agreement

Schedule 1.36:  {E5 Licensed}  Patents

Schedule 3.2: Initial Development & Manufacturing Plan

Schedule 3.5.1: [***]

Schedule 6.2(c): Initial Commercialization Commitments

Schedule 6.3: Contents of Commercialization Plan for Planned Activities

Schedule 16.5: Pre-Approved Subcontractors

Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version LICENSE AND DEVELOPMENT AGREEMENT

This LICENSE AND DEVELOPMENT AGREEMENT (this Agreement) is  {E6 entered}  into effective as of  Nov. 02, 2019  (the Effective  Date  ) by and between Bioeq IP AG,  {E7 having}  its place of business at [***] (Bioeq) and Coherus BioSciences, Inc.,  {E8 having}  its principal place of business at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, 94065, USA (Licensee). Bioeq and Licensee shall also each individually be  {E9 referred}  to herein as a Party, and shall be  {E10 referred}  to jointly as the Parties. RECITALS

WHEREAS, Bioeq is a specialized biosimilar company;

WHEREAS, Bioeq is the owner or exclusive licensee of all right, title and interest to certain products which are being  {E11 developed}  as biosimilars to pharmaceutical products  {E12 comprising}  the monoclonal antibody fragment Ranibizumab and  currently   {E13 marketed}  in the field of ophthalmology under the brand name LucentisÂ®;

WHEREAS, Licensee is a company  {E14 focused}  on the {E159 development} and {E160 commercialization} of biosimilar products; and

WHEREAS, Licensee  {E15 wishes}  to  {E16 obtain}  an exclusive license from Bioeq for the {E161 commercialization} of Ranibizumab biosimilar products being  {E17 developed}  by Bioeq in the United States of America in consideration for upfront, milestone and royalty {E162 payments} to Bioeq, and Bioeq is willing to  {E18 grant}  such license subject to the terms and conditions of this Agreement. NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the Parties hereby  {E19 agree}  as  follows  :

1.DEFINITIONS AND INTERPRETATION

For purposes of this Agreement, the  {E20 capitalized}  terms  {E21 used}  in this Agreement shall have the respective meanings set forth in this Section 1 below. 1.1 Affiliate means with respect to any Party, (a) any legal entity of which the securities or other ownership interests  {E22 representing}  more than 50% of the equity or more than 50% of the ordinary voting power or more than 50% of the general partnership interest are, at the time such {E164 determination} is being  {E27 made}  ,  {E24 owned}  ,  {E25 controlled}  or  {E26 held}  , directly or indirectly, by such legal entity; or (b) any legal entity which, at the time such {E164 determination} is being  {E27 made}  , is  {E28 controlling}  or under common control with, such Party. As  {E29 used}  in this definition, the  term  "control", whether  {E30 used}  as a noun or verb,  {E31 refers}  to the possession, directly or indirectly, of the power to  {E32 direct}  , or  {E33 cause}  the direction of, the {E165 management} or policies of a legal entity, whether through the ownership of voting securities, by contract or otherwise. 1.2 Agreement shall have the meaning  {E34 ascribed}  to it in the introductory paragraph above. 1.3 Applicable Law means any and all applicable federal, state, local and international laws, rules and regulations,  {E35 including}  regulations of competent Regulatory Authorities and environmental laws, as  {E36 amended}  from time to time, and the regulations  {E37 promulgated}  thereunder, as  {E38 amended}  from time to time. 1.4 [***]

Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version 1.5 Biologics License Application or BLA means a {E166 request} for permission to  {E39 introduce}  , or  {E40 deliver}  for {E167 introduction}, a biologic product into interstate commerce (21 CFR 601.2) to the FDA,  {E41 including}  any supplements, addendums, or amendments  {E42 thereto}  . For the avoidance of doubt, the  term  Biologics License Application or BLA shall  {E43 include}  any Abbreviated Biologics License Application. 1.6 Biologics License Application {E169 Approval} means {E169 issuance} of a Department of Health and Human Services U.S. License under 351(k) of the Public Health Services Act  {E44 controlling}  the {E170 manufacture} and {E171 sale} of biologic products or any successor statutory provisions thereof. 1.7 BPCIA means the Biologics Price Competition and Innovation Act of  2009 , as  {E45 amended}  . 1.8 CMO means contract  {E46 manufacturing}  organization. 1.9 Commercially Reasonable {E174 Efforts} means, with respect to the {E172 efforts} to be  {E47 used}  by a Party under this Agreement with respect to the Licensed Products, those {E174 efforts} and resources normally  {E48 used}  by a major pharmaceutical or a sufficiently  {E49 financed}  biotechnology company for a product  {E50 owned}  by it, or to which it has rights, which is of similar market potential at comparable stages of {E175 development},  {E51 taking}  into account the competitiveness of the marketplace, the proprietary position of the product, the {E176 performance} of other products that are of similar market potential and the likely timing of other product's {E177 entry} into the market, the regulatory structure  {E52 involved}  , the profitability of the applicable product, relevant Third Party intellectual property necessary to  {E53 manufacture}  or Commercialize the Licensed Product and other relevant factors commonly  {E54 considered}  in similar circumstances,  {E55 including}  technical, legal, scientific or medical factors. 1.10 {E179 Commercialization} means the {E179 conduct} of all {E180 activities}  {E56 undertaken}  before and after Regulatory Approval  {E57 relating}  to the {E181 promotion}, {E182 marketing}, {E183 sale} and {E184 distribution} ( {E58 including}   {E59 importing}  ,  {E60 exporting}  , transporting, customs clearance, warehousing, invoicing, handling and  {E61 delivering}  products to customers) of pharmaceutical products,  {E62 including}  : (a) sales force {E185 efforts}, {E186 detailing}, {E187 advertising}, medical {E188 education}, {E189 planning}, {E190 marketing}, sales force {E191 training} and {E192 sales} and {E193 distribution}; and (b) scientific and medical {E194 affairs}. For clarity, {E179 Commercialization}  does  not  {E63 include}  any Development {E196 activities}, whether  {E64 conducted}  before or after Regulatory {E228 Approval}. "Commercialize" and "Commercializing" have correlative meanings. 1.11 Competitive Product means (i) any product which  {E65 contains}  Ranibizumab and is either a Reference Product or a biosimilar to a Reference Product, but  {E66 excluding}  in any case the Licensed Products, (ii) [***] (but for clarity [***]) or (iii) [***] (but for clarity [***]). 1.12 Competitor means any person or entity (other than the Parties and their Affiliates) which has  {E67 initiated}  and is then-active in [***] the {E198 marketing}, {E199 selling} or {E200 distribution} of a Competitive Product, [***] in the Territory, as well as any Affiliate of any such person or entity. 1.13 Competitor {E202 Change} of Control means any of the  {E68 following}  {E201 events} after the Effective  Date  :

(a) any Competitor (i)  {E69 becomes}  the beneficial owner, directly or indirectly, of shares of capital stock or other interests ( {E70 including}  partnership interests) of the Licensee then outstanding and normally  {E71 entitled}  (without regard to the {E295 occurrence} of any {E296 contingency}) to  {E72 vote}  in the {E203 election} of the directors, managers or similar supervisory positions (Voting Stock) of such Party  {E73 representing}  more than fifty percent (50%) of the total  {E74 voting}  power of all outstanding classes of Voting Stock of the Licensee or (ii) has the power, directly or indirectly, to  {E75 appoint}  a majority of the Licensee's  {E76 managing}  directors or to  {E77 elect}  a majority of the members of the Licensee's board of directors, supervisory board or similar governing body (Board of Directors); or

Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version (b) the Licensee  {E78 enters}  into a {E207 merger}, {E208 consolidation} or similar {E209 transaction} with a Competitor (whether or not such Party is the  {E79 surviving}  entity) and as a result of such {E207 merger}, {E208 consolidation} or similar {E209 transaction} (i) the  {E80 managing}  directors or the members of the Board of Directors of the Licensee immediately prior to such {E211 transaction}  {E81 constitute}  less than a majority of the  {E82 managing}  directors or the members of the Board of Directors of the Licensee or such  {E83 surviving}  person immediately  following  such {E211 transaction} or (ii) the persons that beneficially  {E84 owned}  , directly or indirectly, the shares of Voting Stock of the Licensee immediately prior to such {E213 transaction} cease to beneficially own, directly or indirectly, shares of Voting Stock of the Licensee  {E85 representing}  a majority of the total  {E86 voting}  power of all outstanding classes of Voting Stock of the  {E87 surviving}  person in substantially the same proportions as their ownership of Voting Stock of the Licensee immediately prior to such {E213 transaction}. 1.14 Confidential Information means, with respect to a Party, all  Know  -How and all other proprietary information of such Party,  {E88 including}  information on the business, {E214 affairs}, research and development {E215 activities}, results of non-clinical and clinical {E216 trials}, national and multinational regulatory {E217 proceedings} and {E218 affairs}, finances, plans, contractual relationships and {E219 operations} of such Party. Furthermore, the terms and conditions of this Agreement shall be  {E89 considered}  Confidential Information of both Parties. For the avoidance of doubt, all  Know  -How and proprietary information  {E90 relating}  to the Licensed Products  {E91 generated}  by or on behalf of Bioeq and  {E92 provided}  to Licensee hereunder shall be  {E93 considered}  Confidential Information of Bioeq. 1.15 Control (whether  {E94 used}  as a noun or as a verb) or  {E95 Controlled}  means, with respect to any Intellectual Property Right, Trademark or Know-How, the possession (whether by ownership or license, other than pursuant to this Agreement) by a Party of the ability to  {E96 grant}  to the other Party access or a license as  {E97 provided}  herein under such Intellectual Property Right, Trademark or Know-How without  {E98 violating}  the terms of any agreement or other arrangements with any Third Party. 1.16 {E220 Damages} shall have the meaning  {E99 ascribed}  to it in Section 9.4.3. 1.17 Defend or {E221 Defense} shall have the meaning  {E100 ascribed}  to it in Section 9.4.2. 1.18 {E229 Development} means all non-clinical and clinical research and drug development {E223 activities} as well as Manufacturing process {E224 development}, {E225 upscaling} of the Manufacturing process and chemistry, {E226 manufacturing} and control development {E227 work}  {E101 conducted}  in respect of any pharmaceutical product,  {E102 including}  those necessary to  {E103 obtain}  Regulatory {E228 Approval} for such pharmaceutical product. When  {E104 used}  as a verb, Develop means to  {E105 engage}  in {E229 Development}. 1.19 Disclosing Party shall have the meaning  {E106 ascribed}  to it in Section 11.1. 1.20 Effective  Date  shall have the meaning  {E107 ascribed}  to it in the introductory paragraph above. 1.21 Existing Reference Product shall have the meaning  {E108 ascribed}  to it in Section 1.61. 1.22 FDA means the United States Food and Drug Administration, and any successor agency thereto. 1.23 Field means any human {E230 use} of the Licensed Product in the field of ophthalmology and for any other  {E109 approved}  labelled {E231 indication} of such Licensed Products. 1.24 First Commercial {E233 Sale} means, with respect to any Licensed Product in the Territory, the first {E233 sale} by Licensee or its Affiliates of such Licensed Product to a Third Party for {E236 use} in the Field in the Territory, after such Licensed Product has been  {E110 granted}  Regulatory {E228 Approval} for {E236 use} in the Field in the Territory. Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version 1.25 [***] means [***]

1.26 [***] Agreement means the license agreement  {E111 existing}  between Bioeq and [***]  {E112 dated}  as of [***] and  {E113 attached}  to this Agreement as Annex 1. 1.27 Gross Margin means Net Sales for the {E237 sale} of any Licensed Product less (a) [***] the supply price  {E114 paid}  by Licensee or its Affiliates to Bioeq for the {E238 supply} of such Licensed Product under the Manufacturing and Supply Agreement ( {E115 including}  any Sales Tax thereon  {E116 paid}  by Licensee to Bioeq and not  {E117 refunded}  back to Licensee in accordance with Section 8.1) [***], (b) {E239 Damages}, and (c)  {E118 Qualifying}  IP Clearance Litigation Costs. Gross Margin will be  {E119 calculated}  on a Licensed Product-by- Licensed  Product and calendar  quarter  -by-calendar  quarter  basis in accordance with Section 7.3.3. 1.28 {E298 Improvement} means any {E286 Invention}  {E148 developed}  ,  {E121 conceived}  or  {E122 reduced}  to  {E123 practice}  by or on behalf of either Party in relation to any Licensed Product during the  term  of this Agreement, but for clarity  {E124 excluding}  any New Products. 1.29 Indemnified Party shall have the meaning  {E125 ascribed}  to it in Section 13.3(a). 1.30 Indemnifying Party shall have the meaning  {E126 ascribed}  to it in Section 13.3(a). 1.31 Infringement {E240 Claim} shall have the meaning  {E127 ascribed}  to it in Section 9.4.2. 1.32 {E241 Insolvency Event} means:

1.32.1 In relation to Licensee: (a) the {E242 making} by it of a general {E243 assignment} for the benefit of creditors; (b) the {E244 commencement} by it of any voluntary petition in {E245 bankruptcy} or {E246 suffering} by it of the {E247 filing} of an involuntary petition of its creditors; (c) the {E248 suffering} by it of the {E249 appointment} of a receiver to  {E128 take}  possession of all, or substantially all, of its assets; (d) the {E250 suffering} by it of the {E251 attachment} or other judicial {E252 seizure} of all, or substantially all, of its assets; (e) the {E253 admission} by it in writing of its inability to  {E129 pay}  its debts as they  {E130 come}  due; or (f) the {E254 making} by it of an {E255 offer} of {E256 settlement}, {E257 extension} or {E258 composition} to its creditors generally. 1.32.2 In relation to Bioeq: (a) its {E284 over-indebtedness} (Ãberschuldung), (b) its {E285 inability} to  {E131 make}  {E259 payments} as and when they  {E132 fall}  due (ZahlungsunfÃ¤higkeit), (c) it  {E133 ceasing}  to  {E134 make}  {E260 payments} on account of debts as and when they  {E135 fall}  due (Zahlungseinstellung), (d) the {E261 commencement} of {E262 negotiations} with its creditors with a view to  {E136 rescheduling}  its indebtedness, (e) the {E263 initiation} by Bioeq of any {E264 proceedings} for {E265 bankruptcy} (Konkurs), the {E266 postponement} of {E267 bankruptcy} (Konkursaufschub) or the {E268 grant} of a composition {E269 moratorium} (Nachlassstundung), (f) the {E270 opening} of {E271 proceedings} for {E272 bankruptcy}, the {E273 postponement} of {E274 bankruptcy} or the {E275 grant} of a composition {E276 moratorium} with respect to Bioeq upon {E277 request} of a Third Party (g) the {E278 sequestration} (Arrestierung), {E279 attachment} or {E280 seizure} of, or the {E281 appointment} of a receiver or administrator with respect to, all or substantially all of its assets or (f) the {E282 occurrence} of any {E283 event} which is similar in its effect to (a) through (f) under any Applicable Laws. 1.33 Intellectual Property Rights means, with respect to any technology, (a) all Patent Rights which  {E137 claim}  or  {E138 cover}  such technology, and (b) all other  {E139 existing}  and future intellectual property rights (but not any  {E140 Know}  -How)  {E141 relating}  to such technology,  {E142 including}  all legally  {E143 protected}  trade secrets, copyrights and other intellectual property rights of any kind, but  {E144 excluding}  any Trademark. 1.34 In-Licensed Licensed Patents means all Licensed Patents which are exclusively  inâ{E157 licensed}  by Bioeq,  {E145 including}  those Patent Rights exclusively in- {E146 licensed}  by Bioeq from [***] pursuant to the [***] Agreement ([***] -{E147 Licensed}  Patents). Source: COHERUS BIOSCIENCES, INC., 10-K,  2/27/2020

Confidential Execution Version 1.35 {E286 Invention} means any {E287 invention}, technology, {E288 improvement}, {E289 change}, {E290 modification} or {E291 enhancement}  {E148 developed}  ,  {E149 conceived}  or  {E150 reduced}  to  {E151 practice}  by or on behalf of either Party during the  term  of this Agreement. 1.36 Know-How means all technical, scientific and other information, {E293 inventions}, {E292 discoveries}, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures,  {E152 expressed}  ideas, technical {E294 assistance}, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, Development information, results, non-clinical, clinical, safety, process and Manufacturing and quality control data and information ( {E153 including}  trial designs and protocols), registration dossiers and assay and biological methodology, in each case, solely to the extent confidential and proprietary and in  {E154 written}  , electronic or any other form  now   {E155 known}  or hereafter  {E156 developed}  .



#COLOR:E164=hsl(0, 100%, 80%)
#COLOR:E27=hsl(25, 100%, 80%)
#COLOR:E169=hsl(50, 100%, 80%)
#COLOR:E174=hsl(75, 100%, 80%)
#COLOR:E179=hsl(100, 100%, 80%)
#COLOR:E207=hsl(125, 100%, 80%)
#COLOR:E208=hsl(150, 100%, 80%)
#COLOR:E209=hsl(175, 100%, 80%)
#COLOR:E211=hsl(200, 100%, 80%)
#COLOR:E213=hsl(225, 100%, 80%)
#COLOR:E229=hsl(250, 100%, 80%)
#COLOR:E228=hsl(325, 100%, 80%)
#COLOR:E233=hsl(275, 100%, 80%)
#COLOR:E236=hsl(300, 100%, 80%)
#COLOR:E286=hsl(350, 100%, 80%)
#COLOR:E148=hsl(0, 100%, 70%)

#TOKENIZATION-TYPE:1

